Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
复制标题
DOI：
10.1186/s13148-016-0203-8
复制
发表时间：
2016
影响因子：
5.7
通讯作者：
Kang GH
中科院分区：
文献类型：
--
作者：
Chen D;Wen X;Song YS;Rhee YY;Lee TH;Cho NY;Han SW;Kim TY;Kang GH
LINE-1在肿瘤中的低甲基化状态与结肠癌患者的低生存率有关。东部合作肿瘤组绩效状态(ECOG-PS)是一种评估患者功能状态的方法。我们回顾评估了在接受5-氟尿嘧啶/亚叶酸钙/奥沙利铂(FOLFOX)辅助治疗的结直肠癌或结肠癌患者中，ECOG-PS和LINE-1甲基化之间的关系及其对预后的影响。分析III期或高危期II期(n = 336)的LINE-1甲基化和微卫星不稳定性。LINE-1甲基化水平与包括PS和无复发生存率(RFS)在内的临床病理特征相关。观察到肿瘤LINE-1甲基化水平与PS之间的关联(OR = 2.56，P <； 0.001)。在60岁以上患者(P = 0.001)、超重体重指数组(P = 0.005)和III期疾病组(P = 0.008)中，PS 0和1组之间的癌组织LINE-1甲基化水平差异显著。LINE-1甲基化状态或联合PS和LINE-1甲基化状态在III期结肠癌中具有预后意义，而在III期和高危II期癌中不具有预后意义。低LINE-1甲基化状态与较短的RFS时间密切相关。PS(0)/LINE-1(高)和PS(≥1)/LINE-1(低)之间的差异有统计学意义，提示结肠癌合并PS(≥1)/LINE-1(低)复发率较高。结直肠癌组织中PS与LINE-1甲基化相关。在接受辅助性FOLFOX化疗的III期结肠癌患者中，Line-1甲基化与RFS相关。联合应用PS和LINE-1甲基化状态可作为预测癌症复发的有用指标。本文的在线版本(doi：10.1186/s13148.0160203-8)包含补充材料，授权用户可以使用。
Low methylation status of LINE-1 in tumors is associated with poor survival in patients with colon cancer. Eastern Cooperative Oncology Group performance status (ECOG-PS) is a method to assess the functional status of a patient. We retrospectively evaluated the relationship between ECOG-PS and LINE-1 methylation in colorectal cancers (CRCs) and their prognostic impact in CRC or colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX). LINE-1 methylation and microsatellite instability were analyzed in stage III or high-risk stage II CRCs (n = 336). LINE-1 methylation levels were correlated with clinicopathological features, including PS and recurrence-free survival (RFS). The association between the tumoral LINE-1 methylation level and PS was observed (OR = 2.56, P < 0.001). Differences in LINE-1 methylation levels in cancer tissue between the PS 0 and 1 groups were significant in patients older than 60 years (P = 0.001), the overweight body mass index group (P = 0.005), and the stage III disease group (P = 0.008). Prognostic significances of LINE-1 methylation status or combined PS and LINE-1 methylation statuses were identified in stage III colon cancers, not in stage III and high-risk stage II CRCs. Low LINE-1 methylation status was closely associated with a shorter RFS time. The difference between PS(0)/LINE-1(high) and PS(≥1)/LINE-1(low) was significant, which suggests that colon cancer patients with concurrent PS(≥1)/LINE-1 (low) have a higher recurrence rate. PS was associated with LINE-1 methylation in CRC tissue. LINE-1 methylation was associated with RFS in stage III colon cancer patients who were treated with adjuvant FOLFOX chemotherapy. Combined PS and LINE-1 methylation status might serve as a useful predictor of cancer recurrence. The online version of this article (doi:10.1186/s13148-016-0203-8) contains supplementary material, which is available to authorized users.